These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Rituximab therapy in pemphigus: A long-term follow-up. Loi C; Magnano M; Ravaioli GM; Sacchelli L; Patrizi A; Bardazzi F Dermatol Ther; 2019 Jan; 32(1):e12763. PubMed ID: 30288877 [No Abstract] [Full Text] [Related]
9. [Rituximab as treatment for refractory pemphigus in Mexican patients]. Cruz-Meza S; Ruiz-Arriaga LF; Barrón-Tapia MT; Estrada-Aguilar L Rev Alerg Mex; 2021; 68(1):7-11. PubMed ID: 34148324 [TBL] [Abstract][Full Text] [Related]
10. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus. Londhe PJ; Kalyanpad Y; Khopkar US Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353 [TBL] [Abstract][Full Text] [Related]
11. Rituximab in the management of juvenile pemphigus foliaceus. Loh TY; Paravar T Dermatol Online J; 2017 Jun; 23(6):. PubMed ID: 28633733 [TBL] [Abstract][Full Text] [Related]
12. Rituximab as the treatment of pemphigus vulgaris in the COVID-19 pandemic era: A narrative review. Beyzaee AM; Rahmatpour Rokni G; Patil A; Goldust M Dermatol Ther; 2021 Jan; 34(1):e14405. PubMed ID: 33051960 [TBL] [Abstract][Full Text] [Related]
13. Iatrogenic Kaposi's sarcoma induced by rituximab and corticosteroid treatment for pemphigus vegetans in an HIV-negative patient. Daflaoui H; Saddouk H; Ouadi I; Zizi N; Dikhaye S Indian J Dermatol Venereol Leprol; 2022; 88(3):409-412. PubMed ID: 35434989 [No Abstract] [Full Text] [Related]
14. [Treatment of severe refractory pemphigus vulgaris with rituximab]. Pitarch G; Sánchez-Carazo JL; Pardo J; Torrijos A; Roche E; Fortea JM Actas Dermosifiliogr; 2006; 97(1):48-51. PubMed ID: 16540052 [TBL] [Abstract][Full Text] [Related]
15. [Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases]. Alter M; Wittmann M; Völker B; Kapp A; Werfel T; Gutzmer R Hautarzt; 2009 Sep; 60(9):743-8. PubMed ID: 19151961 [TBL] [Abstract][Full Text] [Related]
16. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients. Brown AE; Motaparthi K; Hsu S Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653 [TBL] [Abstract][Full Text] [Related]
17. Case of a severe vulgaris and foliaceus pemphigus in a young patient treated with rituximab, with subsequent development of chronic urticaria. Rovesti M; Pierobon E; Vaschieri C; Genovese G; Marzano AV; Lotti T; Satolli F; Feliciani C Dermatol Ther; 2020 Jul; 33(4):e13665. PubMed ID: 32500603 [No Abstract] [Full Text] [Related]
18. Rituximab-induced psoriasis in a patient with pemphigus foliaceous: A case report and literature review. Charoenpipatsin N; Chularojanamontri L; Rujitharanawong C; Tuchinda P; Kulthanan K J Dermatol; 2022 Aug; 49(8):e251-e252. PubMed ID: 35384046 [No Abstract] [Full Text] [Related]
19. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. Mahmoudi H; Tavakolpour S; Balighi K; Farid AS; Nili A; Jan D; Daneshpazhooh M Dermatol Ther; 2021 Jan; 34(1):e14633. PubMed ID: 33280226 [TBL] [Abstract][Full Text] [Related]
20. Rituximab induced reticulate pigmentation over face in pemphigus vulgaris. Sanke S; Mendiratta V; Jassi R; Yadav J; Chander R Dermatol Ther; 2020 Jul; 33(4):e13752. PubMed ID: 32519811 [No Abstract] [Full Text] [Related] [Next] [New Search]